Caldic UK Ltd signs exclusive agreement with Tagra Biotechnologies for extensive encapsulation range
Chesterfield, 4 February 2020 – Caldic is proud to be appointed as exclusive UK distribution partner of Israel-based Tagra Biotechnologies for their extensive encapsulation range. With this new agreement, the full-service distributor further expands its existing portfolio for the UK Cosmetic and Personal Care markets.Tagra Biotechnologies, leading manufacturer and supplier of microencapsulated ingredients, has been providing innovative and highly functional active microencapsulated ingredients to the cosmetic and personal care industries since 1998. They are world leader in Release on Demand™ (RND™) Microencapsulation Technology, a patented method providing stability, efficiency and controlled and immediate release for non-water soluble ingredients. Tagra’s range of ingredients includes micron-size encapsulated UV filters, essential oils vitamins and pigments.
“We are excited at the prospect of introducing Tagra’s complete range of products to our customers”, says Michiel Kerkhoven, Business Development Manager Europe Personal Care of Caldic B.V.
“The innovative ways in which their products help to protect, enhance and signal formulation effectiveness – all by cleaver use of encapsulation technologies- is simply outstanding. Tagra’s innovative technology is a great fit with Caldic’s own strategy to enhance and develop our life sciences business sector. We are confident that going forward, together we will be able to add extra value to customers’ business while continuing to offer novel product applications for consumers.”
Lito Ickowicz, Tagra Biotechnologies’ Director Business Development: “Tagra looks forward to a successful partnership with Caldic UK and to offer customers high quality technical service and innovative application insights.”
Tagra’s microencapsulation range will be available through Caldic UK Ltd. from February 1. Should you require any further information regarding this agreement, please contact Martin Gunson.